Skip to content
Screener

Design Therapeutics, Inc. DSGN Asset turnover

Asset turnover at other companies

ALN
Alnylam PharmaceuticalsALNY
0.9×+0.4×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
0.1×0.0×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0×0.0×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
0.1×-0.8×
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
0×0.0×
uniQure logo
uniQureQURE
0×0.0×

Other financials

Income statement

See full
Revenue-—
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$875.52M+219%
Enterprise value$865.48M+237%

Profitability

See full
Operating margin-3,685.8%—
Net margin-3,663.7%—

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0×0.0×
Current ratio22.3×-6.1×

Where this comes from

Calculated from Design Therapeutics, Inc.’s reported figures.

total revenue/total assets=0×

Based on trailing twelve months.

The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026. Open the filing →

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-187063

FAQ

What is Design Therapeutics, Inc.'s asset turnover?
Design Therapeutics, Inc. (DSGN) reported asset turnover of 0× in Q1 2026.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.

Ask your AI about Design Therapeutics, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude